Goldman Sachs Puts Pfizer’s 2012 China Sales at $3 Billion

In an investment review of Pfizer, Goldman Sachs said sales in emerging growth markets would become a significant factor in the company’s revenues, a fact that it considers underappreciated by stock market investors. China is the major emerging market for Pfizer. Goldman expects emerging growth markets to produce $3.5 billion of revenue for Pfizer in 2012, and $3 billion of that will come from China. More details... Stock Symbol:  (NYSE: PFE)